@article{435c9d2f53ec449e8d778764aa58dc93,
title = "Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative",
abstract = "This overview describes the generation and development of the ideas that led to the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative. It also describes the organization, process, and products of the first meeting. The CNTRICS initiative involves a series of three conferences that will systematically address barriers to translating paradigms developed in the basic animal and human cognitive neuroscience fields for use in translational research aimed at developing novel treatments for cognitive impairments in schizophrenia. The articles in this special section report on the results of the first conference, which used a criterion-based consensus-building process to develop a set of cognitive constructs to be targeted for translation efforts.",
keywords = "Cognitive neuroscience, schizophrenia, translational research, treatment development",
author = "Carter, {Cameron S.} and Barch, {Deanna M.} and Buchanan, {Robert W.} and Ed Bullmore and Krystal, {John H.} and Jonathan Cohen and Mark Geyer and Michael Green and Nuechterlein, {Keith H.} and Trevor Robbins and Steven Silverstein and Smith, {Edward E.} and Milton Strauss and Til Wykes and Robert Heinssen",
note = "Funding Information: Cameron S. Carter receives funding from the NIMH, the Robert Wood Johnson Foundation, and National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD). Dr. Carter has served as a consultant for Pfizer, Eli Lilly, and Roche. Deanna M. Barch receives funding from the NIMH, the McDonnell Foundation, and NARSAD. Dr. Buchanan is currently a data and safety monitoring board (DSMB) member for Pfizer and in the past has served as a DSMB member for Wyeth. He has served as a consultant for Pfizer, Roche, Memory Pharmaceuticals, Glaxo-Smith-Kline, Astra-Zeneca, Solvay, Sanofi-Aventis, and Organon and has received study medications from Janssen and Ortho-McNeil Neurologics. Dr. Bullmore is an employee of the University of Cambridge (.5 full-time equivalent [FTE]) and GlaxoSmithKline (GSK) (.5 FTE); a stockholder in GSK and the Brain Resource Company; and has received financial compensation resulting from a license agreement between Cambridge Enterprise Limited, University of Cambridge, Cambridge, United Kingdom, and Cypress Bioscience Inc., San Diego, California. Dr. Geyer has received consulting compensation from Abbott, Acadia, Addex, Amgen, AstraZeneca, Bristol-Myers Squibb, Jazz, Organon, Nura, San Diego Instruments, Serono, and Wyeth-Ayerst. Dr. Geyer also has research grant support from National Institute on Drug Abuse (NIDA), NIMH, and the U.S. Veteran's Administration, Veterans Integrated Service Network (VISN) 22 Mental Illness Research, Education, and Clinical Center. Dr. Green received funding form the NIMH and serves as a consultant to Amgen, Acadia, Astellas, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Eli Lilly, Lundbeck, Memory Pharmaceuticals, Otsuka Pharmaceutical, Sanofi-Aventis Pharmaceuticals, and Solvay. Dr. Krystal receives research funding from the NIMH and has served as an advisor or consultant for AstraZeneca Pharmaceuticals, LP Bristol-Myers Squibb, Cypress Bioscience, Inc., Eli Lilly and Co., Forest Laboratories, GlaxoSmithKline, HoustonPharma, Lohocla Research Corporation, Merz Pharmaceuticals, Organon Pharmaceuticals, Pfizer Pharmaceuticals, Tetragenex Pharmaceuticals, and Transcept Pharmaceuticals, Inc. Dr. Nuechterlein has received research funding from the NIMH and from Janssen, L.P. and has served as a consultant for Janssen, L.P. Dr. Robbins is a stockholder in CeNeS and has share options in Cambridge Cognition. He has served as a consultant to Eli Lilly, GSK, Wyeth, and Allon. Dr. Robbins has received research funding from Pfizer and GSK Inc. and received speaking honoraria from Merck, Sharp, and Dohm, Lundbeck, Cephalon, and Cortex. Dr. Silverstein receives funding from the NIMH, NARSAD, Stanley Medical Research Institute, Janssen, and AstraZeneca. Dr. Straus, Dr. Heinssen, Dr. Smith, and Dr. Wykes reported no biomedical financial interests or conflicts of interest. Dr. Cohen receives research funding from the NIMH.",
year = "2008",
month = jul,
day = "1",
doi = "10.1016/j.biopsych.2008.03.020",
language = "English (US)",
volume = "64",
pages = "4--10",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "1",
}